Latanoprost/timolol
In today's world, Latanoprost/timolol is a topic that has gained great relevance and has generated intense debate in different areas. Since its emergence, Latanoprost/timolol has captured the attention of academics, professionals and the general public, generating conflicting opinions and provoking deep reflections on its impact on society. In this article, we will explore different perspectives on Latanoprost/timolol and analyze its influence on various aspects of everyday life. From its origin to its consequences, we will delve into an in-depth analysis that will allow us to better understand this phenomenon and its implications for the future.
| Combination of | |
|---|---|
| Latanoprost | Prostaglandin |
| Timolol | Beta blocker |
| Clinical data | |
| Trade names | Xalacom |
| Routes of administration | Eye drops |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
Latanoprost/timolol, sold under the brand name Xalacom, is a combination drug used for the treatment of glaucoma, consisting of latanoprost (increase uveoscleral outflow of aqueous humor[3]) and timolol (a beta blocker decreasing the production of aqueous fluid).
Society and culture
Brand names
In some countries, Xalacom is marketed by Viatris after Upjohn was spun off from Pfizer.[4][5]
References
- ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
- ^ "Summary of Product Characteristics (SmPC)". (emc). 13 June 2022. Retrieved 31 March 2024.
- ^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.
- ^ "Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan". Pfizer. 16 November 2020. Retrieved 17 June 2024 – via Business Wire.
- ^ "Brands". Viatris. 16 November 2020. Retrieved 17 June 2024.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |